Laura R. Murphy, RN

Dawes Fretzin Clinical Research Group, LLC
7910 North Shadeland Avenue
Indianapolis, Indiana 46256
Phone (317) 516-5030 Ext 103
Fax (317) 516-5148
Email: lsuchy@ecommunity.com

Dawes Fretzin Dermatology Group, LLC
7910 North Shadeland Avenue
Indianapolis, Indiana 46256
Phone (317) 516-5030 Ext 103
Fax (317) 516-5148

Education

Marian University, (Indianapolis, IN)
Bachelor of Science Nursing, May 2013

DePauw University, (Greencastle, IN)
Bachelor of Arts, Psychology, May 2008

Hinsdale Central High School (Hinsdale, IL)
High School Diploma, May 2004

Professional Experience

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Study Coordinator, November 2016-Present

Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Registered Nurse, November 2016-Present

Community North Breast Care (Indianapolis, IN)
Registered Nurse, June 2014- November 2016

Indiana University Health, Hematology and Oncology (Indianapolis, IN)
Registered Nurse, June 2013- June 2014

Indiana University Health, Hematology and Oncology (Indianapolis, IN)
Patient Care Intern, December 2012- June 2013

License/Certifications

State of Indiana Registered Nurse, #28209355A
BLS/CPR Certification
CITI Certification, November 2016, October 2017, July 2021
IATA Certification, November 2016, October 2020
TB Certification
ACLS Certification

Clinical Study Experience

Psoriasis:

Sponsor: Janssen
A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chonic Plaque Psoriasis in Pediatric Subjects >/= 6 to < 12 Years of Age; January 2017 to Present.

Laura R. Murphy, RN

Sponsor: UCB BioPharma
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmocodynamics of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis. October 2016- Present

Sponsor: Kadmon
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Efficacy of KD025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy. September 2016- Present

Sponsor: Novartis
A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate the efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis.August 2016- Present

Sponsor: Boehringer Ingelheim
BI 655066 versus Ustekinumab and placebo comparatros in a ramdomized double-blind trial for Maintenance use in Moderate to severe plaque type psoriasis-2 (U1tIMMa-2) –
March 2016 – Present

Atopic Dermatitis

Sponsor: Pfizer
A Phase 2B Randomized, Double-Blind, Placebo-Controlled, Parallel, Multicenter, Dose-Ranging, Study to Evaluate the Efficacy and Safety Profile of PF-04965842 in subjects with Moderate to Severe Atopic Dermatitis.April 2016- Present

Sponsor: GlaxoSmithKline
A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the T reatment of Atopic Dermatitis - February 2016 to Present

Sponsor: Regeneron Pharmaceuticals
A Phase 3, Randomized, Doulbe-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis July 2015 to February 2017

Sponsor: Regeneron Pharmaceuticals
An Open-Label Study of Dupilumab In Patients with Atopic Dermatitis Who Participated In Previous Dupilumab Clinical Trials - June 2015 to Present

Sponsor: Regeneron Pharmaceuticals
A phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis February 2015 to June 2016

Laura R. Murphy, RN

Acne

Sponsor: Foamix
A Randomized, Double-Blind Study to compare the efficacy, safety and Long-term safety of topical administration or FMX-101 for 1 year in the treatment of Moderate-to-Severe Acne Vulgaris. July 2016- Present

Sponsor: Valeant
A Phase 1b Open-Label, Randomized Sutyd Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-123 Lotion in Comparison with Tazorac Cream 0.1% in Subjects with Acne Vulgaris under Maximal Use Conditions. – June 2016- Present

Sponsor: Valeant
A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris -October 2015 to Present

Sponsor: Ranbaxy
Phase 4, An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne -February 2015 to Present

Actinic Keratosis

Sponsor: Therapeutics, Inc
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of a Generic Ingenol Mebutate Gel, 0.015% and Picato Gel, 0.015% in Subjects with Actinic Keratosis on the Face or Scalp July 2016 to Present

Common Warts

Sponsor: RXi Pharmaceuticals
A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone) on the Clearance of Verruca Vulgaris (Common Warts) in Subject Ages 18-65 Years. July 2016 – Current